News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Subgroup analyses boost masupirdine potential for AD
15 Aug 2022
byAudrey Abella
Post hoc data from a phase II study presented at AAIC 2022 continue to demonstrate the potential of masupirdine (SUVN-502), a selective 5-HT6 receptor antagonist, as a treatment alternative for the management of neuropsychiatric and cognitive symptoms of Alzheimer’s disease (AD).
15 Aug 2022

HCV reinfection highest among people with ongoing injecting drug use
14 Aug 2022
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.
14 Aug 2022






